Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Previous years tags : Liver save search
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | $4.67 1.74% 1.71% 930K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 4.76%
H: 0.45%
C: -5.91%
drug candidate liver cancer treat namodenoson advanced
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: 64.34%
H: 4.82%
C: -18.67%
fxr314 metabolic liver positive for results
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 2.12%
H: 0.7%
C: -0.82%
liver treatment fibrosis pharmaceuticals for advanced nash
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
Published: 2024-04-08 (Crawled : 17:00) - globenewswire.com
INKT | $0.898 3.02% 2.93% 40K
|
|
| O: 1.28%
H: 0.0%
C: -16.46%
nk-215 liver cancer preclinical therapeutics
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
SRZN | $9.33 9.39% 2K
|
|
| O: -8.98%
H: 4.61%
C: -29.37%
szn-043 liver
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
Published: 2024-03-28 (Crawled : 00:00) - prnewswire.com
OCEA | $1.76 -6.13% -6.53% 200K
|
|
| O: 0.49%
H: 0.0%
C: -7.23%
vron-0200 hepatitis liver global immunotherapy meeting virus study
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Published: 2024-03-15 (Crawled : 13:00) - prnewswire.com
GLMD | $0.3787 -0.41% 18K
|
Health Technology
|
| O: 17.48%
H: 0.0%
C: -25.59%
mgl-3196 patent liver treatment fibrosis grant aramchol nash
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 20.66%
H: 2.07%
C: -8.01%
fda liver approval treatment fibrosis pharmaceuticals advanced
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
Published: 2024-03-06 (Crawled : 14:00) - globenewswire.com
INKT | $0.898 3.02% 2.93% 40K
|
|
| O: 1.02%
H: 0.48%
C: -1.41%
nk-215 liver cancer preclinical
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
Published: 2024-03-06 (Crawled : 14:00) - biospace.com/
INKT | $0.898 3.02% 2.93% 40K
|
|
| O: 1.02%
H: 0.48%
C: -1.41%
nk-215 liver cancer tumor preclinical
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: -0.86%
H: 2.04%
C: 1.66%
liver authorization treatment fibrosis pharmaceuticals ema application
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
OCEA | $1.76 -6.13% -6.53% 200K
|
|
| O: 2.6%
H: 36.71%
C: 11.39%
first liver presentation global meeting therapeutics study
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Published: 2024-02-26 (Crawled : 07:00) - globenewswire.com
ZEAL | News | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma liver disease fibrosis trial results
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
Published: 2024-02-20 (Crawled : 15:30) - biospace.com/
BTTX | $0.009 -65.02% 180K
|
|
| O: 7.55%
H: 2.13%
C: -27.83%
fda device liver disease designation therapeutics advanced platform
Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver
Published: 2024-02-13 (Crawled : 13:00) - globenewswire.com
NNOX | $8.62 -4.96% -5.22% 1M
|
Health Technology
|
| O: -6.78%
H: 2.42%
C: -3.55%
fda liver software clearance advanced
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.35%
H: 2.36%
C: 1.42%
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 27.92%
H: 0.97%
C: 0.88%
liver acquisition sciences therapeutics
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
NUWE | $0.255 -2.07% -2.12% 230K
|
Manufacturing
|
| O: 6.25%
H: 0.78%
C: -12.75%
aquadex liver disease series potential therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.